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ABSTRACT: Understanding the activation and internalization of G protein-coupled receptors (GPCRs) using conditional
approaches is paramount to developing new therapeutic strategies. Here, we describe the design, synthesis, and testing of
ExONatide, a benzylguanine-linked peptide agonist of the glucagon-like peptide-1 receptor (GLP-1R), a class B GPCR required
for maintenance of glucose levels in humans. ExONatide covalently binds to SNAP-tagged GLP-1R-expressing cells, leading to
prolonged cAMP generation, Ca2+ rises, and intracellular retention of the receptor. These eﬀects were readily switched OFF
following cleavage of the introduced disulﬁde bridge using the cell-permeable reducing agent beta-mercaptoethanol (BME). A
similar approach could be extended to a class A GPCR using GhrelON, a benzylguanine-linked peptide agonist of the growth
hormone secretagogue receptor 1a (GHS-R1a), which is involved in food intake and growth. Thus, ExONatide and GhrelON
allow SNAP-tag-directed activation of class A and B GPCRs involved in gut hormone signaling in a reversible manner. This
tactic, termed reductively cleavable agONist (RECON), may be useful for understanding GLP-1R and GHS-R1a function both in
vitro and in vivo, with applicability across GPCRs.
■ INTRODUCTION
G protein-coupled receptors (GPCRs) transduce information
encoded by external stimuli into an appropriate cell output and as
such play a key role in organismal homeostasis.1 For this reason,
GPCRs are important drug targets, yet many facets of their
function remain enigmatic, including how they dynamically
signal in space and time. Selectively targeting and interrogating
GPCRs is therefore important for understanding their function.
Tethered pharmacology describes the linkage of pharmaco-
phores in close proximity to their targets often but not necessarily
in combination with recombinant engineering. By means of
covalent or noncovalent high aﬃnity binding, this approach
allows the precise control of biological function as usually
achieved by genetics, but with the speed of pharmacology.2 Self-
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labeling proteins (e.g., SNAP-, CLIP-, and Halo-tag)3 have
facilitated tethered pharmacology, since they can be condition-
ally expressed and covalently bind molecules possessing the
relevant bioconjugation handle with high selectivity and
enzymatic kinetics.4,5 Moreover, these enzymes can be fused
onto a variety of proteins.6,7 The SNAP-tag is ideal for targeting
GPCRs, as it retains its activity to covalently bind molecules
possessing an O6-benzylguanine (BG) when expressed both in
vitro and in vivo,4,5 and many well-characterized SNAP_GPCR
fusions exist compared to other enzyme self-labels. For instance,
the SNAP-tag is the basis for photoswitchable orthogonal
remotely tethered ligands (PORTLs) for class C GPCRs,2,8,9
while the Halo-tag was anchored to the membrane for the drugs
acutely restricted by tethering (DART) concept.10 However,
PORTLs incorporate an isomerization step for light-controlled
ON/OFF responses, as shown for the metabotropic glutamate
receptor 2 in vivo,11 leaving ligand attached and thus limiting
investigation of receptor traﬃcking and surface versus
internalized populations. On the other hand, DART is
irreversible and does not allow a 1:1 ligand/receptor ratio, albeit
the studies were performed both in vitro and in vivo and
encompassed an ionotropic as well as a metabotropic receptor.
Other approaches, such as bio-orthogonal ligand tethering
(BOLT)12 and photoswitchable tethered ligands (PTLs),13
respectively rely on incorporating unnatural amino acids or
cysteines into proteins. However, their use is limited by the
requirement for site-directed mutagenesis to identify active
mutants or by their inherent reactivity. We therefore reasoned
that a self-labeling protein-tag bearing a cleavable linker would
set the stage for studying conditional, prolonged, and reversible
activation of GPCRs.
The glucagon-like peptide-1 receptor (GLP-1R) is an excellent
candidate for the further development of tethered pharmacology,
since it is a blockbuster drug target for type 2 diabetes
treatment.14 Following ligand binding, this class B GPCR
primarily activates adenylyl cyclase through Gs, leading to 3′-5′-
cyclic adenosine monophosphate (cAMP) accumulation15−17
and intracellular Ca2+ ﬂuxes.18−20 These signaling processes are
terminated by postendocytotic receptor traﬃcking, where the
GLP-1R is internalized into endosomes, followed by either
lysosomal degradation or endosomal recycling to the plasma
membrane.21 However, recent reports suggest that GPCR
signaling continues following receptor internalization into
endosomes via cytosolic cAMP generation.22−24 How internal-
ization and subsequent traﬃcking inﬂuence GLP-1R function is
poorly understood.25 Lastly, the GLP-1R is expressed through-
out the body and displays pleiotropic activity including eﬀects on
glucose levels, locomotion, food intake, blood pressure, and
inﬂammation.14,26−28 Despite this, the contribution of GLP-1R
activation within discrete body compartments and tissues has so
far relied upon Glp1r−/− animals.29−31 Key to better under-
standing GLP-1R, and more broadly GPCR function, is the
development of tools that allow reversible receptor activation in a
highly conditional manner.
Herein, we describe the development and testing of
ExONatide (Figure 1), a benzylguanine-linked and disulﬁde
bridge-containing incretin-mimetic based upon exenatide
(Byetta). ExONatide speciﬁcally labels and activates
SNAP_GLP-1R, a binary response that can be switched OFF
by the simple addition of reducing agent to cleave the ligand
(Figure 1a,b). UsingGhrelON, we also extend the concept to the
growth hormone secretagogue-receptor 1a (GHS-R1a), a class A
GPCR. Following fasting, ghrelin released from the stomach
Figure 1. Logic and synthesis of ExONatide. (a) Crystal structure of the activated GLP-1R in complex with GLP-1 (pdb: 5VAI)74 and SNAP-tag (pdb:
3L00) resemble the molecular dimensions and design of the present study. (b) Schematic showing the reductively cleavable agONist (RECON)
concept: after covalent labeling of a SNAP-tag with ExONatide, the GLP-1R can be activated, leading to Ca2+ and cAMP rises together with
internalization and traﬃcking, which can readily be terminated by reductive cleavage using beta-mercaptoethanol (BME). (c) The cleavable disulﬁde
bridge of ExONatide is formed through reaction of BG-PEG4-SSpy with S39C-Ex4.
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binds and activates GHS-R1a in neurons located in the arcuate
nucleus of the hypothalamus, as well as pituitary somatotropes,
leading to orexigenic (feeding) responses and growth hormone
secretion.32−34 As such, ExONatide and GhrelON provide the
blueprint for reductively cleavable agONist (RECON) peptides
and set the scene for conditionally targeting GPCRs both in vitro
and in vivo.
■ RESULTS
Design and Synthesis of ExONatide. As shown by X-ray
crystal structures, incretin-mimetic peptides with agonistic
activity such as exenatide (Byetta; also known as exendin-4 or
Ex4(1−39)) bind to the GLP-1R with their C-terminus solvent
exposed.35,36 We therefore set out to derivatize Ex4(1−39) by
mutating and synthesizing the S39C-Ex4 variant by means of
solid-phase peptide synthesis (SPPS) to install a free cysteine
bioconjugation handle at the C-terminus. Linking BG-NH2 to a
PEG4 spacer containing a pyridyl-activated disulﬁde from
commercially available substrates, and by reacting this with
S39C-Ex4, ExONatide was obtained in high purity on the
milligram scale (see Supporting Information for details on
synthesis and characterization) (Figure 1c). ExONatide there-
fore comprises a SNAP-tag reactive BG linked to a GLP-1R
agonist via a reductively cleavable disulﬁde-containing PEG4
chain.
ExONatide Activates and Labels SNAP_GLP-1R. Ex4(1−
39) was able to increase intracellular cAMP concentrations with
an EC50 (30 min) = 17.9 ± 1.2 pM in YFP-AD293-SNAP_GLP-
1R cells, as assessed using LANCE TR-FRET-based assays
(Figure 2a). By contrast, cAMP concentration−responses to
ExONatide were right-shifted (EC50 (30 min) = 95.2± 8.2 pM),
with similar results seen in AD293-GLP-1R_GFP cells lacking
the SNAP-tag (Figure 2a,b). Suggesting that single amino acid
substitutions at the solvent exposed C-terminus of the peptide
may have an eﬀect on potency, the EC50 values for the S39C-Ex4
precursor (EC50 (30 min) = 98.8 ± 5.5 pM) and ExONatide
were almost identical (Figure 2a). Nonetheless, maximal cAMP
responses were near 100% (vs 5 μM forskolin) for all compounds
tested, implying full agonism (Figure 2a).
SNAP-tag labeling eﬃciency was determined by preincubating
YFP-AD293-SNAP_GLP-1R cells with ExONatide for 30 min
before washing and adding BG-TMR, a fast cell-permeable
SNAP-labeling ﬂuorophore. Increasing concentrations of
ExONatide exponentially reduced BG-TMR intensity with a
half-maximal binding concentration (BC50 (30 min) = 32.1 ±
22.7 nM) suggestive of near-quantitative SNAP-tag labeling at
the membrane (Figures 2c,e, S1, S2a). Labeling reached 70−
80%, which may reﬂect internalization of 20−30%GLP-1R at the
time of application of ExONatide, which is non-cell permeable
compared to BG-TMR, or alternatively 20−30% loss of
internalized receptor due to degradation at high ExONatide
concentrations.23,37 Supporting the latter, a 20−30% decrease in
BG-TMR ﬂuorescence was also seen following incubation of
YFP-AD293-SNAP_GLP-1R cells with high concentrations (>1
μM) of Ex4(1−39) (Figure 2c,f). ExONatide was similarly able
to label AD293-SNAP_mGluR2_GFP cells (Figure 2d,g),
Figure 2. ExONatide signaling and binding. (a) ExONatide, S39C-Ex4 and Ex4(1−39) cAMP concentration−responses in YFP-AD293-SNAP_GLP-
1R cells (n = 3 assays in triplicate). (b) ExONatide concentration−response curves are similar with andwithout the SNAP-tag (n = 3 assays in triplicate).
(c) Preincubation with increasing concentrations of ExONatide exponentially decreases BG-TMR binding/ﬂuorescence compared to Ex4(1−39) in
YFP-AD293-SNAP_GLP-1R cells (n = 177−448 cells). (d) ExONatide (1−10 μM) decreases BG-TMR binding/ﬂuorescence in AD293-
SNAP_mGluR2_GFP cells (n = 137−176 cells). (e and f) Representative images showing BG-TMR ﬂuorescence in YFP-AD293-SNAP_GLP-1R cells
preincubated with and without a high concentration (1 μM) of ExONatide or Ex4(1−39) (scale bar = 33 μm). (g) Representative images showing BG-
TMR ﬂuorescence in AD293-SNAP_mGluR2_GFP cells preincubated with and without a high concentration (10 μM) of ExONatide (scale bar = 33
μm). Values are the mean ± SEM.
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although labeling strength was reduced, probably due to loss of
the orthosteric site that may contribute to aﬃnity labeling (58.8
± 2.6 vs 37.0 ± 1.5% binding, SNAP_GLP-1R vs SNAP_
mGluR2_GFP cells, respectively; 1 μM ExONatide; P < 0.01,
Student’s t test). No binding was detected in YFP-only
transfected cells, as expected for the SNAP-tag speciﬁc BG-
compound (Figure S2b). On the basis of the SNAP-tag labeling
eﬃciency, ExONatide was used at a concentration of 800 nM for
all subsequent cell biology experiments.
Figure 3. ExONatide leads to prolonged Ca2+ and cAMP signaling. (a) ExONatide induces Ca2+ rises in MIN6B1-SNAP_GLP-1R cells similarly to
Ex4(1−39), but this cannot be washed out with buﬀer (mean± SEM traces shown) (gray shaded area T1-T3 = analysis time window) (n = 29−34 cells).
(b) Application of beta-mercaptoethanol (BME) for 5 min immediately prior to washout allows Ca2+ responses to ExONatide to be subsequently
reduced (mean ± SEM traces shown) (gray shaded area T4−T6 = analysis time window) (n = 34 cells). (c) Representative images showing Ca2+
responses to ExONatide in MIN6B1-SNAP_GLP-1R cells before (T4), during (T5) and after (T6) application of BME. (d) Bar graph showing
amplitude of Ca2+ responses to Ex4(1−39) and ExONatide before and after washout± BME (n = 29−34 cells) (T1-T6 relate to time windows shown in
a and b). (e) Box and whiskers plot showing that ExONatide-stimulated insulin secretion can only be washed out following application of BME (n = 8
wells) (Ex4(1−39)-alone was used as a positive control) (G11; 11mMglucose). (f) As for (a), but FRET assays for intracellular cAMP 15min following
application of ligand or washout (n = 40−71 cells). (g) Representative images showing FRET responses to ExONatide in MIN6B1-SNAP_GLP-1R
cells before and after application of BME. (h) BME was unable to signiﬁcantly induce apoptosis over 60 min, as determined using immunostaining for
cleaved caspase 3 (CC3) (overnight incubation serves as the positive control) (n = 3 experiments). **P < 0.01 and NS, nonsigniﬁcant, as indicated or vs
control; Student’s t test, one-way ANOVA (with Bonferroni’s or Tukey’s posthoc test) or Kruskal−Wallis test (with Dunn’s multiple comparison test).
ExONatide and Ex4(1−39) were applied at 800 nM and 10 nM, respectively. BME was applied at 10 mM. Values are the mean± SEM unless otherwise
stated.
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Figure 4. Reversible GLP-1R internalization by ExONatide. (a) Representative images showing that application of the agonist Ex4(1−39) toMIN6B1-
SNAP_GLP-1R cells at high glucose concentration (11 mM; G11) induces GLP-1R internalization, which can be partially reversed with the antagonist
Ex4(9−39) (G3; 3mMglucose) (scale bar = 10 μm). (b) As for (a), but following application ofExONatide. Note that GLP-1R internalization can only
be reversed by Ex4(9−39) following application of beta-mercaptoethanol (BME). (c) Surface GLP-1R expression is signiﬁcantly reduced following
application of Ex4(1−39), and this is reversed by application of Ex4(9−39). (d) Surface GLP-1R expression in MIN6B1-SNAP_GLP-1R cells is
signiﬁcantly reduced following application of ExONatide, but this is not reversed by application of Ex4(9−39). (e) As for (d), but showing plasma
membrane recycling of GLP-1R following treatment with BME. (f) ExONatide-internalized GLP-1R in MIN6B1-SNAP_GLP-1R cells partially
colocalizes with early endosome antigen 1 (EEA1) (top panels), and this is maintained in the presence of Ex4(9−39) (scale bar = 10 μm). **P < 0.01
andNS, nonsigniﬁcant vs G3 (one-way ANOVAwith Tukey’s posthoc test). In (c) and (d), samples were run in parallel, hence the same control value (n
= 3−7 experiments). ExONatide, Ex4(1−39), and Ex4(9−39) were applied at 800 nM, 10 nM, and 10 μM, respectively. BME was applied at 10 mM.
Values are the mean ± SEM.
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ExONatide Does Not Induce GLP-1R Biased Signaling.
Biased signaling exists when diﬀerent agonists selectively engage
diﬀerent signaling pathways via the same receptor. Several GLP-
1R agonists engender bias between G-protein signaling
(measured as cAMP production) and β-arrestin-dependent
phosphorylation of ERK1/2.38 To determine whether
ExONatide is a biased GLP-1R agonist, we measured signaling
responses using CHO-K1-SNAP_GLP-1R cells together with
the intramolecular FRET reporters TEpacvv39 and cytoplasmic
EKAR,40 which respectively measure intracellular cAMP
production and ERK1/2 activation via conformational changes
in proximity between CFP and YFP derivatives. Ratiometric
changes in ﬂuorescence were apparent on stimulation with
Ex4(1−39), S39C-Ex4, and ExONatide at nanomolar concen-
trations (Figure S3a,b), and concentration−response curves for
each pathway were obtained (Figure S3c,d). As all compounds
were full agonists in each pathway, relative potency ratios
(ΔΔLogEC50) were used to calculate bias.
41 Relative to Ex4(1−
39), neither S39C-Ex4 nor ExONatide exhibited bias between
cAMP and ERK signaling, as determined with sequential
measurements over 30 min to avoid kinetic artifacts (Figure
S3e).42
ExONatide Induces Conditional and Prolonged GLP-1R
Signaling in Beta Cells.We next sought to investigate whether
Figure 5. GhrelON structure, signaling, and binding. (a) Structure of GhrelON showing the cleavable disulﬁde bridge and PEG-linker. (b)
GhrelinGGCG and GhrelON display minimal loss of binding aﬃnity for the GHS-R1a, as measured using speciﬁc Tag-lite competition assay (n = 2
assays in triplicate). (c) Ghrelin, ghrelinGGCG, and GhrelON demonstrate similar potencies for IP-1 generation (n = 2 assays in triplicate). (d)
Preincubation of YFP-AD293-SNAP_GHS-R1a cells withGhrelON decreases BG-TMR binding/ﬂuorescence intensity compared to native ghrelin (n
= 230−385 cells). (e) GhrelON decreases BG-TMR binding/ﬂuorescence in AD293-SNAP_mGluR2_GFP cells (n = 338−435 cells). (f and g)
Representative images showing BG-TMR ﬂuorescence in YFP-AD293-SNAP_GHS-R1a cells preincubated with and without a high concentration (1
μM) ofGhrelON or ghrelin (scale bar = 33 μm). (h) As for (f) but AD293-SNAP_mGluR2_GFP cells treated with or without 10 μMGhrelON. Values
are the mean ± SEM.
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Figure 6. GhrelON reversibly activates and internalizes the GHS-R1a. (a) Both ghrelin and GhrelON induce large increases in intracellular Ca2+
concentrations in YFP-AD293-SNAP_GHS-R1a, although washout of ligand only restores baseline Ca2+ levels for ghrelin (mean± SEM traces shown)
(gray shaded area T1−T3 = analysis time window) (n = 27−54 cells). (b) Application of beta-mercaptoethanol (BME) for 5 min immediately prior to
washout reduces Ca2+ responses toGhrelON to baseline levels (mean± SEM traces shown) (gray shaded area T4-T6 = analysis time window) (n = 27−
54 cells). (c) Bar graph showing amplitude of Ca2+ responses to ghrelin and GhrelON before and after washout ± BME (n = 27−54 cells) (T1−T6
relate to time windows shown in a and b). (d) Treatment of YFP-AD293-SNAP_GHS-R1a cells with ghrelin for 1 h leads to GHS-R1a internalization,
which can be partially reversed following washout and incubation for a further 3 h. GhrelON exerts similar eﬀects, but these can only be washed out
following prior application of BME for 10 min (n = 10−12 images from two experiments). (e) Representative images showing that ghrelin reduces
surface GHS-R1a expression (detected via the FLAG-tag), which is reversed by a wash step (scale bar = 33 μm). f) As for (e), but showing that plasma
membrane GHS-R1a recycling can only be achieved by application of BME to GhrelON-treated YFP-AD293-SNAP_GHS-R1a cells. **P < 0.01 and
NS, nonsigniﬁcant, as indicated; Student’s t test or one-way ANOVA (with Bonferroni’s posthoc test). Ghrelin and GhrelON were applied at 100 nM
and 800 nM, respectively. BME was applied at 10 mM. Values are the mean ± SEM.
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ExONatide would activate GLP-1R signaling in a physiologically
more relevant system, i.e., in MIN6 beta cells. This was done by
following GLP-1-induced Ca2+ ﬂuxes using confocal microscopy.
Both Ex4(1−39) and ExONatide induced large cytosolic Ca2+
rises in Fluo8-loaded MIN6B1-SNAP_GLP-1R cells (Figure
3a−d). While resting baseline Ca2+ levels could be restored
following a washout period for Ex4(1−39), this was not the case
for ExONatide where Ca2+ remained signiﬁcantly elevated
(Figure 3a−d). However, addition of beta-mercaptoethanol
(BME) for 5 min immediately before washout allowed Ca2+
responses to ExONatide to be reduced (Figure 3b−d). In line
with [Ca2+]i measurements, ExONatide stimulated insulin
secretion similarly to Ex4(1−39), although this could only be
halted following reductive cleavage and washout of compound
(Figure 3e).
Similar results were observed using the FRET-based biosensor
Epac2-camps.43While ExONatide induced an increase in cAMP,
which could be partially washed out in the absence of reducing
agent, baseline cAMP levels were only achieved following prior
application of BME for 10 min. We note that MIN6B1-
SNAP_GLP-1R cells endogenously express GLP-1R that may
give rise to background adenylyl cyclase activity, although this did
not appear to be a major issue, since cAMP responses to
ExONatidewere reduced to control levels by BME (Figure 3f,g).
An eﬀect of reducing agent per se is unlikely, as Ca2+ responses to
Ex4(1−39) were unaﬀected by BME (Figure 3b−d). Moreover,
BME did not inﬂuence insulin secretion at 11 mM D-glucose
(Figure 3e), or cAMP responses to Ex4(1−39) (Figure 3f).
Together, these data provide evidence for reversible signaling
through the two main GLP-1R activation pathways in pancreatic
beta cells.
BME was used for reductive cleavage, since it is cell permeable
and the GLP-1R undergoes internalization following activa-
tion.37 While BME may conceivably induce toxicity and loss of
function through modiﬁcation of cell proteins including the
receptor itself, this did not seem to be an issue in the present
studies. Even following 60 min incubation with 10 mM BME,
cells did not display signiﬁcant signs of necrosis (Figure S4a) or
apoptosis (Figure 3h), although cleaved caspase 3 was
signiﬁcantly upregulated after overnight exposure (Figure 3h).
Furthermore, MIN6 cells remained proliferative and viable in
culture 2 days after 0−60 min exposure to BME, suggesting that
reductive alterations to proteins are unlikely to inﬂuence cell
phenotype over the long-term (Figure S4b,c). ATP responses to
D-glucose were similar in control and BME-treated MIN6 cells,
demonstrating normal metabolism (Figure S4d). Lastly, cAMP
concentration−responses to Ex4(1−39), ExONatide, and
S39C-Ex4 were all unaﬀected by 10 min preincubation with
BME (Figure S5).
ExONatide Allows Long-Lasting and Reversible GLP-
1R Internalization. Following agonist binding, the GLP-1R
undergoes internalization before ligand removal and endosomal
sorting, either for recycling back to the plasma membrane or
lysosomal degradation.23,25 Receptor recycling is a highly
regulated process, and receptors that cannot disengage ligands
are expected to remain sequestered within the endosome. To
examine the eﬀects of constitutive activation on receptor
internalization, MIN6B1-SNAP_GLP-1R cells were treated
with either Ex4(1−39) or ExONatide before immunohisto-
chemistry for GLP-1R localization using a monoclonal antibody.
Both Ex4(1−39) and ExONatide induced receptor internal-
ization, as shown by a decrease in cell surface GLP-1R
localization and an increase in punctate intracellular staining
(Figures 4a−d, S6). However, this was only reversed by the
speciﬁc antagonist for Ex4(9−39), with no signiﬁcant plasma
membrane recycling detected for ExONatide (Figures 4a−d,
S6). Supporting a role for SNAP-tag-binding in irreversible
internalization, recycling of the GLP-1R to the plasmamembrane
was seen following addition of both BME and Ex4(9−39)
(Figure 4b,e). As for Ca2+ and cAMP signaling, BME alone did
not alter receptor internalization (Figure S7).
Following 1 h application of ExONatide, internalized GLP-1R
showed partial (∼50%) colocalization with early endosome
antigen 1 (EEA1), which is broadly in line with that previously
reported at the same time point.37 Pertinently, this association
was maintained even in the presence of Ex4(9−39) after 3 h
(Figure 4f). Not all early endosomes were GLP-1R immuno-
positive (Figure 4f), however, indicating that either the receptor
passes via EEA1+ endosomes before accessing other populations,
or some EEA1+ endosomes no longer contain receptor at this
stage.
Design and Synthesis of GhrelON. To demonstrate the
broad applicability of our approach across class A and B GPCRs,
we decided to install a bioconjugation handle on ghrelin, an
orexigenic hormone involved in food intake and growth through
GHS-R1a binding.32 By contrast to the convenient serine−
cysteine substitution in S39C-Ex4 as the precursor for
ExONatide, ghrelin comprises a C-terminal arginine that is
highly conserved throughout mammalian ghrelin peptides.44 As
the N-terminus is crucial for ghrelin potency and speciﬁcity, with
the N-terminal pentapeptide GSS(C8:0)FL being the minimal
fragment equipotent to ghrelin,45 we decided to retain the full-
length sequence extended by a GGCG fragment. The benzyl
guanine moiety was then merged with the ghrelinGGCG peptide
by formation of a disulﬁde bond with BG-PEG4-SSpy. By using
the same strategy and chemical building blocks as for
ExONatide, we obtained GrehlON on the milligram scale (see
Supporting Information for details on synthesis and character-
ization) (Figure 5a).
GhrelON Activates and Labels SNAP_GHS-R1a. Ghrelin
binds the GHS-R1a with high aﬃnity (Ki = 1.8 ± 0.3 nM),
measured using HTRF-based competition assays (Figure 5b).
GhrelON showed a small loss in binding aﬃnity at the GHS-R1a
(Ki = 6.1 ± 0.6 nM), which may be related to modiﬁcation of the
C-terminus to accept the bioconjugation handle (ghrelinGGCG
also showed decreased binding aﬃnity) (Ki = 19.6 ± 8.1 nM)
(Figure 5b). Similar results were seen for IP-1 accumulation, with
a small loss in potency detected for GhrelON (EC50 = 5.5 ± 0.5
nM) and ghrelinGGCG (EC50 = 11.15 ± 0.4 nM) versus ghrelin
(EC50 = 3.2 ± 0.8 nM) (Figure 5c). GhrelON labeled the
SNAP_GHS-R1a with almost equal eﬃciency (Figure 5d,f,g) to
that detected with ExONatide and the SNAP_GLP-1R. While
100% labeling was not reached, again this probably reﬂected a
reduction in the number of cell-surface receptors available for
peptide labeling due to GHS-R1a internalization in the absence
of ligand (Figure 5d).46 Indicating the presence of aﬃnity
labeling, SNAP-tag binding was also reduced in AD293-
SNAP_mGluR2_GFP cells lacking the orthosteric site for
ghrelin (Figure 5e,h).
GhrelON Allows Prolonged but Reversible GHS-R1a
Activation and Internalization. Both ghrelin and GhrelON
induced large and sustained increases in cytoplasmic Ca2+ levels
in YFP-AD293-SNAP_GHS-R1a cells, most likely through IP3-
dependent liberation of Ca2+ from intracellular stores (Figure
6a).32,47 Whereas Ca2+ responses to ghrelin could be completely
reversed following washout (Figure 6a,c), those of GhrelON
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were more persistent, showing an approximately 50% decrease
(Figure 6a,c). Prior incubation with BME for 5 min before
washout allowed Ca2+ levels to be subsequently restored to
baseline levels in GhrelON-treated YFP-AD293-SNAP_GHS-
R1a cells (Figure 6b,c). To examine receptor traﬃcking, YFP-
AD293-SNAP_GHS-R1a cells were treated with ghrelin or
GhrelON for 1 h before FLAG-immunostaining for the
SNAP_GHS-R1a. Ghrelin induced GHS-R1a internalization
(Figure 6d,e), with recycling back to the cell surface evident 3 h
after agonist washout (Figure 6d,e). While GhrelON also
induced GHS-R1a internalization (Figure 6d,f), this was only
reversed following application of BME for 10 min before the
wash step (Figure 6d,f). Treatment with BME for 10 min before
application of ghrelin did not inﬂuence GHS-R1a internalization
(Figure S8).
■ DISCUSSION
In the present study, we describe an incretin-mimetic termed
ExONatide that allows tethered activation and internalization of
the GLP-1R, a class B GPCR, when N-terminally fused to a
SNAP-tag. We also show that this technology is applicable to a
class A GPCR using GhrelON, which targets the SNAP-tagged
GHS-R1a. In both cases, use of a disulﬁde bridge allows the
reductive release of ligand and resumption of normal signaling
processes, an approach called RECON. Thus, we further develop
tethered pharmacology by using peptide ligands of class A and B
GPCRs involved in the regulation of metabolism.
Prolonged activation of GPCRs has been described previously
by means of cloning activating peptides onto the N-termini48,49
or by coexpression of membrane-anchored peptides for probing
ion channel or GPCR function.50,51 However, using a SNAP-
tagged receptor in conjunction with a BG-linked ligand bears
several advantages: (i) the ligand/receptor ratio is deﬁned as 1:1
in terms of binding and potency; (ii) local concentration with a
PEG4 chain can be considered high
10,52 and does not rely on
membrane ﬂuctuations; (iii) preactivation during expression and
culture is absent; (iv) disturbances in vitro and in vivo are limited
solely by SNAP-tag fusion; (v) it is bidirectional and can be
switched ON and OFF in a binary fashion by virtue of the
incorporated cleavage site; (vi) ligand can be freed from covalent
tethering, allowing the study of normal traﬃcking processes
mediated by orthosteric binding; and (vii) receptor subtypes can
potentially be targeted.
RECON compares favorably to other tethered approaches,
such as PORTL and DART,8−10 and provides two major
advances: a chemically cleavable tether and a peptidic drug.
However, PORTL and DART still possess distinct advantages
including spatiotemporally precise photoswitching or proven
eﬃcacy in vivo, the latter allowing investigation of behavioral
neuropharmacology.10 Thus, future studies will seek to use
RECON as a platform to introduce these aspects, for example, via
photoswitch incorporation, targeting ion channels, or intra-
cellular proteins and in vivo testing.
Suggesting that the modiﬁcations required for tethering are
well-tolerated, the potency of ExONatide and GhrelON for
cAMP and IP-1 generation was only reduced 1 order of
magnitude compared to native Ex4(1−39) and ghrelin,
respectively. This may be due to the amino acid substitutions,
since a similar loss of potency was detected for both the S39C
variant of Ex4(1−39) and ghrelinGGCG. It can be assumed that
further derivatization at this position to obtain the highly
modiﬁed ExONatide or GhrelON would lower potency even
more, but that any loss may be oﬀset by covalent attachment at
the receptor. Importantly, the ligand concentration required for
orthosteric activation was much less than that required for full
SNAP-tag labeling (pM versus μM), meaning that ExONatide
and GhrelON bound to SNAP_GLP-1R and SNAP_GHS-R1a
fusions are always active.
The AD293-SNAP_GLP-1R cells used in the present study
likely represent an ampliﬁed system, since the EC50 values were
in the pM range.While this makes calculation of the Emax diﬃcult,
ExONatide is still able to drive cAMP/Ca2+ rises and insulin
release in MIN6 cells despite an apparently lowered EC50 versus
Ex4(1−39). Moreover, the EC50 for ExONatide was similar in
CHO cells stably expressing SNAP_GLP-1R and the high
dynamic range FRET sensor TEpacvv. Suggesting that activation
of the GLP-1R may occur in a cooperative manner, the Hill
coeﬃcient for cAMP generation by ExONatide was 1.42 ± 0.16
(1.25 ± 0.07 for S39C-Ex4).
ExONatide induced long-lasting GLP-1R redistribution to the
endosomal compartment that could only be reversed following
addition of a cell-permeable reducing agent. Although SNAP-
labeled ﬂuorophores with cell surface-restricted disulﬁde
cleavage sites have been reported,53 they still rely on receptor
activation by a native ligand. By contrast, ExONatide provides a
physiological relevant tool for probing how class B GPCRs signal
within organelles (e.g., endosomes), as well as how alterations in
kinetics may inﬂuence second messenger recruitment (i.e., signal
bias), all based upon intracellular manipulation. Indeed,
ExONatide, Ex4(1−39) and S39C-Ex4 displayed similar
EC50’s for cAMP and ERK, suggesting that (i) diﬀerences in
agonist behavior are unlikely to be due to signal bias in the
context of transmembrane versus intracellular activation; and (ii)
GLP-1R internalization induced by ExONatide likely reﬂects
signaling duration rather than intensity.
GLP-1R and GHS-R1a signaling have broad-ranging physio-
logical functions. While conditional knockout mouse models
exist,54 methods for selectively activating the receptors with
ligands are lacking. CRISPR/Cas9 genome editing has, however,
allowed the generation of epitope-tagged mice,55 and expressing
endogenous SNAP-fusion proteins in rodents can be envisioned.
Accordingly, ExONatide and GhrelON in combination with
SNAP_GLP-1R or SNAP_GHS-R1a animals may provide a
powerful platform for dissecting out the role of GLP-1R and
GHS-R1a signaling in a cell-speciﬁc manner in vivo. The
pharmacokinetics of ExONatide and GhrelON will need careful
assessment before any in vivo workup, and noncleavable
congeners lacking the disulﬁde bridge may be required to
avoid reactivity with glutathione and other cysteine-containing
proteins including serum albumin. However, recent studies have
shown that disulﬁdes are well-tolerated in vivo when incorpo-
rated into ligands as a backbone for cell-selective dual agonists.56
As an alternative to BME, which may be diﬃcult to administer to
an animal at high doses without apparent toxicity, the disulﬁde
bridge can be cleaved by diﬀerent modes of action in vivo, e.g., by
reduced lipoic acid or harsh UV−C light.57 Furthermore, other
approaches to “uncage” molecules, for instance, by using Pd-
chemistry58 or bioorthogonal click and release reactions59−61
have been reported, and these molecular scaﬀolds may replace
the disulﬁde bond in the future as options for in vivo application.
Compared to other pharmacological approaches, the RECON
system aﬀords unique opportunities in terms of understanding
GPCR function in vitro: (i) endogenous GPCR signaling can be
activated in a speciﬁc cell population within a complex tissue
(e.g., catecholaminergic GLP-1R-expressing neurons in brain
slices62); (ii) receptors with closely related ligands can be
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engaged with almost 100% speciﬁcity (i.e., GLP-1R, GLP-2R,
and GCGR, which all bind hormones derived from post-
translational processing of the proglucagon polypeptide63); (iii)
the eﬀects of intracellular ligand activity (e.g., transcriptional
regulation64 and functional selectivity65) can be studied by
controlling receptor recycling and degradation; and (iv) it
becomes possible to study the inﬂuence of ligand dissociation
constant (kon and koff) and residence time of ligands on biased
behavior in diverse GPCRs.66 As such, we expect RECON and
more widely tethered pharmacology to reveal novel facets of
GPCR function.
Lastly, high concentrations of BME were required for
reductive cleavage of both ExONatide and GhrelON. While
apoptosis, necrosis, and metabolic indices were all apparently
normaleven after prolonged 60 min exposure to BMEwe
cannot exclude an eﬀect of reducing agent on cell viability.
Moreover, BME did not inﬂuence GLP-1R or GHS-R1a
signaling and traﬃcking, but other parameters such as exact
ligand dissociation kinetics could not be easily investigated in the
present studies using Tag-lite assays due to SNAP-tag occupancy,
although this could feasibly be done with radioligands. Further
studies are thus needed to understand whether and how BME
would interfere more widely with cell proteins/receptor
function, especially since the GLP-1R and GHS-R1a contain
N-terminal disulﬁdes essential for proper receptor folding. It
should be noted that the cytosolic environment is highly
reducing, with reported glutathione levels of ∼8 mM.67
Bioreductive cleavage is unlikely to inﬂuence activity of
internalized ExONatide and GhrelON, since surface expression
of the GLP-1R and GHS-R1a was not signiﬁcantly altered 3 h
after a wash step or application of antagonist. However, we
cannot exclude that bioreduction of the disulﬁde bridge may alter
other aspects of internalized ligand behavior not evaluated in the
present study.
In summary, ExONatide and GhrelON provide templates for
the design and production of agonists and constitute, to the best
of our knowledge, the largest tethered drugs produced to date.
Both allow prolonged yet reversible activation of cell surface
receptor proteins, such as GPCRs, bearing a fused self-labeling
protein tag. Ligands with other distinct properties, such as
antagonists and/or modulators, or even branched versions
bearing reporters, including dyes or MRI/contrast agents, can
now be envisioned, and this is ongoing research in our
laboratories.
■ METHODS
Synthesis. Solid phase peptide synthesis and characterization
of ExONatide and GhrelON is detailed in the Supporting
Information.
Modeling. A structural model for the ExONatide bound
SNAP_GLP-1R was built using pymol with the pdb structures
3L00 (SNAP-tag reacted with BG) and 5VAI (GLP-1 bound to
GLP-1R). The 28 N-terminal amino acids of the GLP-1R were
not resolved and are therefore depicted as a dashed line. The
extended GLP-1 to resemble ExONatide, and the linker
(disulﬁde bridge and PEG4 spacer) was built using the residue
and fragment tool. We note that the structure only resembles
molecular dimensions and is not energy optimized.
Cell Lines. AD293 cells were kept in Dulbecco’s Modiﬁed
Eagles medium (DMEM) with 10% fetal calf serum (FCS), 1% L-
glutamine and 1% penicillin/streptomycin, and incubated at 37
°C, 5% CO2. HEK293T cells stably expressing the human GHS-
R1a (HEK293T-GHS-R1a) were maintained in DMEM
Glutamax + high glucose supplemented with 10% heat-
inactivated FCS, 50 U/mL penicillin, 50 μg/mL streptomycin,
1 mg/mLG418, 2 mMHEPES and 1% nonessential amino acids.
CHO-K1 cells stably expressing the SNAP_GLP-1R (CHO-K1-
SNAP_GLP-1R) were maintained in DMEM supplemented
with 10% FCS, 1% penicillin/streptomycin, 500 μg/mL G418, 5
mM glucose, 10 mM HEPES and 1% nonessential amino acids.
MIN6 beta cells stably expressing the SNAP_GLP-1R
(MIN6B1-SNAP_GLP-1R) were grown in DMEM supple-
mented with 15% FCS, 25 mM D-glucose, 71 μMBME, 2 mM L-
glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin
supplemented with 100 U/mLG418, and incubated at 37 °C, 5%
CO2.
SNAP-Tag Binding Assays. AD293 cells were cotransfected
with either SNAP_GLP-1R and YFP (YFP-AD293-SNAP_GLP-
1R) or SNAP_GHS-R1a and YFP (YFP-AD293-SNAP_GHS-
R1a) (both Cisbio) using PolyJet reagent (SignaGen) according
to the manufacturer’s instructions. Cells were incubated for 30
min with Ex4(1−39), ghrelin, ExONatide, or GhrelON, before
washing and counter-labeling with 0.5 μM BG-TMR for 30 min.
Cells were imaged using Zeiss LSM780/880 meta-confocal
microscopes conﬁgured with GaAsP PMT spectral detectors and
10×/0.45 W and 63×/1.20 W objectives. YFP was excited using
a λ = 514 nm Argon laser, and emitted signals captured from λ =
524−567 nm. BG-TMR was excited at λ = 561 nm, and emitted
signals captured from λ = 570−641 nm. Control experiments
were performed using either mock cells, or AD293 transfected
with SNAP_mGluR2_GFP (AD293-SNAP_mGluR2_GFP),
GLP-1R_GFP (AD293-GLP-1R_GFP), or YFP (AD293-
YFP), as above.
cAMP Assays. Cyclic adenosine monophosphate (cAMP)
levels were measured using a PerkinElmer LANCE TR-FRET kit
according to the manufacturer’s instructions, normalized to a 5
μM forskolin (FSK) maximal response and plotted as % change.
Treatments were applied as indicated to suspended cells in a
Greiner low-volume 384-well plate for 10 or 30 min in the
presence of 100 μM 3-isobutyl-1-methylxanthine (IBMX),
before lysis to extract total cAMP. Excitation was performed at
λ = 340 nm, and emitted signals detected at both λ = 615 nm and
λ = 665 nm using a BMG PHERAStar microplate reader. Control
experiments were performed in AD293 cells transfected with
GLP-1R_GFP or in the presence of 10 mM BME.
Biased Signaling Measurements. The FRET reporters
TEpacvv (mTurquoise-Venus) (a kind gift from Kees Jalink) and
cytoplasmic EKAR (CFP-YFP) (a kind gift from Karel Svoboda)
were cotransfected into CHO-K1-SNAP_GLP-1R cells together
with a puromycin resistance plasmid. Clones were then
generated using puromycin selection and FACS. FRETmeasure-
ments were performed in black plates, with freshly detached cells
suspended in HBSS, using a Flexstation 3 plate reader (excitation
λ = 440 nm, emission λ = 485 nm and λ = 535 nm for
mTurquoise (CFP) and Venus (YFP), respectively). Serial
measurements every 2 min were taken during a 10 min baseline
and for 30 min after agonist addition at multiple doses.
mTurquoise (CFP) and Venus (YFP) measurements were
expressed ratiometrically and normalized to individual well
baseline.
Relative potency ratios were used to calculate bias, as each
compound was a full agonist in each pathway.41 In each assay,
LogEC50 values were calculated at each time point for each
agonist by 3-parameter ﬁtting. Kinetic changes in LogEC50 were
then ﬁtted with a one-phase decay function, from which
interpolated values were obtained at ﬁner temporal resolution.
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Relative potencies (ΔLogEC50) were obtained by subtracting
LogEC50 values for S39C-Ex4 and ExONatide from that of the
reference agonist Ex4 in each assay at each interpolated time
point. Bias (ΔΔLogEC50) was then determined by subtracting
the relative potency of each test agonist in each pathway. As all
agonists were tested for each pathway in parallel to reduce
variability, bias was calculated on a per assay basis.
Calcium Imaging. MIN6B1-SNAP_GLP-1R or YFP-
AD293-SNAP_GHS-R1a cells were loaded with the Ca2+
indicator Fluo8 (10 μM) for 30 min. Ca2+ imaging was
performed using a Crest X-Light spinning disk head coupled to
a Nikon Ti-E automated base and 10×/0.4 NA objective.
Excitation was delivered at λ = 458−482 nm using a Lumencor
Spectra X Light engine, and emitted signals were detected at λ =
500−550 nm using a Photometrics Evolve Delta 512 EMCCD.
ExONatide, Ex4(1−39),GhrelON, or ghrelin were added to the
imaging chamber for 15−20 min before washing the cells with
buﬀer for 5 min ± BME. Recordings were then continued for a
further 15 min. Intracellular Ca2+ concentration ([Ca2+]i) was
determined as the mean at the time points indicated. For
experiments with MIN6B1-SNAP_GLP-1R, D-glucose was
added at 11 mM, which is permissive for incretin action.
HEPES-bicarbonate buﬀer was used, containing in mM: 120
NaCl, 4.8 KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2,
1.2 MgCl2. For experiments with YFP-AD293-SNAP_GHS-R1a,
samples were maintained in normal culture medium. Intensity-
overtime traces were extracted using a region of interest (ROI)
and for comparison normalized as F/Fmin where F = ﬂuorescence
at a given time point and Fmin = minimum ﬂuorescence.
FRET Imaging. cAMP generation in MIN6B1-SNAP_GLP-
1R cells was measured before and after washout of drug in the
absence or presence of BME using the FRET probe Epac2-
camps.68 Following 10 min incubation, snapshots were captured
using the Crest X-Light spinning disk system, and excitation was
performed at λ = 430−450 nm. Emitted signals were detected at
emission λ = 460−500 nm and λ = 520−550 nm for Cerulean
and Citrine, respectively. Results were expressed as the ratio of
Cerulean/Citrine. In all cases, HEPES-bicarbonate buﬀer was
used.
Insulin Secretion Assays. MIN6B1-SNAP_GLP-1R cells
grown in 12-well plates were incubated with HEPES-bicarbonate
buﬀer supplemented with 0.1% BSA and containing the indicated
treatments for 30 min. For washout experiments, cells were
treated with ExONatide, before washout with and without 10
mMBME for 10min and reincubation with buﬀer for a further 30
min. Insulin concentration in the supernatant was assayed using a
HTRF-based assay (Cisbio) according to the manufacturer’s
instructions.
Apoptosis, Necrosis, and Proliferation Assay. For
quantiﬁcation of apoptosis, MIN6 cells were incubated with 10
mM BME for the indicated times and ﬁxed in 4%
paraformaldehyde. Immunostaining was performed using an
antibody against Cleaved Caspase 3 (CC3; 1:400; #9661, Cell
Signaling Technology), before secondary goat antirabbit Alexa
Fluor 633 (1:1000) and Hoechst 33342 staining. Cells were
imaged using a Zeiss LSM 880 confocal microscope, with
excitation delivered at λ = 405 nm and λ = 633 nm. Emitted
signals were collected at λ = 410−550 nm and λ = 641−695 nm
for Hoechst 33342 and Alexa Fluor 633, respectively. Total area
was quantiﬁed using the threshold plugin for Fiji, and results
were expressed as the ratio CC3/Hoechst, as described.69
For quantiﬁcation of necrosis, MIN6 cells were labeled with 5
μM calcein-AM and 5 μM propidium iodide for 30 min. Cells
were imaged in HEPES-bicarbonate buﬀer using the Crest X-
Light spinning disk system, and excitation was performed at λ =
458−482 nm and λ = 543−558 nm for calcein and propidium
iodide, respectively. Emitted signals were detected at λ = 500−
550 nm and λ = 602−662 nm for calcein and propidium iodide,
respectively. Total area was quantiﬁed using the threshold plugin
for Fiji and expressed as the ratio propidium iodide/calcein, as
described.70
For quantiﬁcation of proliferation, MIN6 cells were ﬁxed and
labeled with Hoechst 33342. Whole wells were imaged using the
Crest X-Light spinning disk system, excitation performed at λ =
383−408 nm, and emitted signals were detected at λ = 435−485.
Images were stitched together, and the total area was analyzed
using the stitching and threshold plugins for Fiji, respectively.
ATP Assay.MIN6 cells were treated with 10 mMBME for 10
min at 37 °C followed by incubation with HEPES buﬀer
containing 3 mM or 20 mM D-glucose for 30 min at 37 °C. ATP
content was detected using the ATP determination kit (A22066;
Thermo Fisher Scientiﬁc) and a BMG PHERAstar microplate
reader, as described.71
GLP-1R Internalization Studies.MIN6B1-SNAP_GLP-1R
cells were incubated in HEPES-bicarbonate buﬀer supplemented
with 3 mM D-glucose for 2 h at 37 °C and either ﬁxed in 4%
paraformaldehyde or further stimulated with 11 mM D-glucose
(G11) containing 10 nM Ex-4(1−39) or 800 nM ExONatide for
1 h at 37 °C. Cells were either ﬁxed or washed extensively prior to
incubation with 10 μM Ex-4(9−39) for a further 1 or 3 h
following 0 or 10 min application of 10 mM BME. At the
concentration used here, Ex4(9−39) is expected to eﬀectively
trap GLP-1R at the plasma membrane, allowing recycling to be
quantiﬁed via reappearance of labeled receptor. Control
experiments were performed using BME and Ex4(1−39)-
alone. Immunostaining was performed using mouse antihuman
GLP-1R (1:30; Mab 3F52; Developmental Studies Hybridoma
Bank) and rabbit anti-EEA1 antibodies (1:50; sc-33585; Santa
Cruz Biotechnology), before secondary antimouse AlexaFluor-
488 staining and mounting on coverslips with Vectashield
Hardset + DAPI. Images were captured using a Zeiss LSM780
microscope and a 63x/1.4 NA oil objective. Excitation was
delivered at λ = 405 nm and λ = 481 nm. Emitted signals were
collected at λ = 410−495 nm and λ = 493−630 nm for DAPI and
AlexaFlour-488, respectively. Surface signal was quantiﬁed on
binarized images using the threshold plugin for ImageJ and
expressed relative to the total signal.
GHS-R1a Ligand Binding Assay. Ki values were
determined from binding competition experiments performed
on HEK293T-GHS-R1a cells using a homogenous time resolved
ﬂuorescence (HTRF) assay (Cisbio), as previously described.72
Ki values were calculated from binding curves.
Inositol Phosphate Assay. Inositol phosphate accumu-
lation assays were conducted 48 h after transfection using
HEK293T-GHS-R1a cells (50 000 cells/well of a 96-well plate).
IP-1 production was measured using the IP-One HTRF kit, as
previously described.73 Values are expressed as ΔF where ΔF =
(ratio 665 nm/620 nm assay − ratio 665 nm/620 nm negative
control)/ratio 665 nm/620 nm negative control. The negative
control, corresponding to the Lumi4-Tb blank, was used as an
internal assay control. Inositol phosphate accumulation was
expressed as the percentage of the maximal ghrelin response
using the formula: (ΔF mock cells − ΔF receptor transfected
cells)/(ΔF mock cells − ΔF maximal ghrelin stimulation for
receptor transfected cells). The basal signal in the absence of any
ligand stimulation corresponded to constitutive activity of GHS-
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R1a (representing 70−75% of maximal stimulation promoted by
ghrelin).
GHS-R1a Internalization Studies. AD293-SNAP_GHS-
R1a cells were incubated with 100 nM ghrelin or 800 nM
GhrelON for 1 h at 37 °C. Cells were either ﬁxed or washed
before incubation for a further 3 h following 0 or 10 min
application of 10 mM BME. Immunostaining was performed
using mouse anti-FLAG antibody (1:200; F1804; Sigma-
Aldrich), before application of secondary antimouse Alexa-
Fluor-568 and mounting on coverslips with Vectashield Hardset
+ DAPI. Images were captured using a Zeiss LSM780
microscope and 63x/1.2 NA water objective. Excitation was
delivered at λ = 405 nm and λ = 561. Emitted signals were
collected at λ = 410−585 nm and λ = 568−691 nm, respectively.
Surface/total signal was quantiﬁed as for the GLP-1R.
Statistics.Data normality was assessed using the D’Agostino-
Pearson test. Nonmultifactorial comparisons were made using
Student’s t test. Multifactorial comparisons weremade using one-
way ANOVA followed by Bonferroni’s or Tukey’s posthoc tests,
or if non-Gaussian, Kruskal−Wallis test followed by Dunn’s
posthoc test. Log-transformed concentration−response curves
were ﬁtted using the Hill equation to allow calculation of EC50
values. All analyses were conducted using GraphPad Prism 6.0
(GraphPad Software) and IgorPro 6.2. Results were considered
signiﬁcant at P < 0.05.
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